Pentostatin

NO UK SPC (eMC) RECORD WAS FETCHED for this bundle - the entire regimen below comes from the US prescribing information for Nipent (Hospira, Inc., label date 2026-07-01, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db62458-cb13-4a2a-b7ee-6ed3fca88a8c) and must be verified against the current UK SPC and local practice. Indication in the fetched label: treatment of hairy cell leukaemia. HYDRATION: patients should receive 500 to 1,000 mL of 5% dextrose in 0.5 normal saline (or equivalent) before administration, plus an additional 500 mL of 5% dextrose (or equivalent) after the dose. RECONSTITUTION: transfer 5 mL Sterile Water for Injection to the vial and mix to give 2 mg/mL; may be given by IV bolus or diluted with 25 mL or 50 mL to give 0.33 mg/mL or 0.18 mg/mL respectively. Reconstituted or diluted solution should be used within 8 hours (no preservatives). DURATION: the optimal duration has not been determined - in the absence of major toxicity and with continuing improvement, treat until a complete response is achieved; administration of two additional doses following a complete response has been recommended (not established as required). Assess all patients at 6 months: discontinue if neither a complete nor a partial response has been achieved; continue if a partial response has been achieved, and give two additional doses whenever a complete response is subsequently achieved, then stop. If the best response at 12 months is a partial response, stop treatment. WITHHOLD/DISCONTINUE: withhold for severe rash; withhold or discontinue for evidence of nervous system toxicity; withhold during active infection and resume when the infection is controlled; withhold temporarily if the absolute neutrophil count falls below 200 cells/mm3 in a patient whose initial neutrophil count was greater than 500 cells/mm3, and resume when the count returns to pre-dose levels. No dosage reduction is recommended at the start of therapy in patients with anaemia, neutropenia or thrombocytopenia, and dose reductions are not recommended during treatment for anaemia and thrombocytopenia if the patient can otherwise be supported haematologically. No extravasation injuries were reported in clinical studies. PAEDIATRIC: safety and effectiveness in children or adolescents have not been established. Any under-18 use must be verified against a children's formulary and specialist paediatric haemato-oncology protocol.